While the proposed MRGPS comprising NOP2, NSUN6, and TET2 can be an alternative prognostic biomarker for ccRCC patients, it is a promising index for personalized ICI treatments against ccRCC. The gene discussed is NSUN6; the disease is nonpapillary renal cell carcinoma.